Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Currently the most frequently used secondary treatment for patients with venous thromboembolism are vitamin K antagonists targeted at an INR of 2.5 (range 2.0 - 3.0). However, based on the continuing risk of bleeding and uncertainty regarding the risk of recurrent venous thromboembolism, there is discussion on the proper duration of treatment with vitamin K antagonists for these patients. Recently, several studies were published in which the risk and benefits of different durations of oral anticoagulants were compared in patients with venous thromboembolism. OBJECTIVES: The objective of this review was to evaluate efficacy and safety of different durations of treatment with vitamin K antagonists in patients with symptomatic venous thromboembolism. SEARCH STRATEGY: The reviewers sought publications through computerized searches of MEDLINE and EMBASE, and by hand-searching relevant journals, using the search strategy described by the Cochrane Review Group on Peripheral Vascular Diseases. They also contacted colleagues. SELECTION CRITERIA: Randomized controlled clinical trials comparing different durations of treatment with vitamin K antagonists in patients with symptomatic venous thromboembolism. DATA COLLECTION AND ANALYSIS: Two reviewers extracted the data and assessed the quality of the trials independently. MAIN RESULTS: Four studies with a total of exactly 1500 patients were included. A consistent reduction for the risk of recurrent events was observed during prolonged treatment with vitamin K antagonists (OR 0.15; 95% CI [0.10 - 0.23]) independent of the period elapsed since the index thrombotic event. A 'rebound' phenomenon, i.e. an excess of recurrences shortly after cessation of the prolonged treatment was not observed (OR 1.11; 95% CI [0.71 - 1.75]). In addition, a substantial increase in bleeding complications was found during the entire period after randomization (OR 7.75; 95% CI [1.08 - 55.57]). REVIEWER'S CONCLUSIONS: In conclusion this meta-analysis shows that treatment with vitamin K antagonists reduces the risk of recurrent venous thromboembolism as long as it is used. However, the absolute risk of recurrent venous thromboembolism declines over time, while the risk for major bleeding remains. Thus, the efficiency of vitamin K antagonist administration decreases over time since the index event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P., et al. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649783 · Cited by 353
Research works printed but not linked: 21
- Kearon, 1999, A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, New England Journal of Medicine, 340, 901, 10.1056/NEJM199903253401201 · DOI · Paper page
- Pinede, 2001, Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis, Circulation, 103, 2453, 10.1161/01.CIR.103.20.2453 · DOI · Paper page
- Schulman, 1995, A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, New England Journal of Medicine, 332, 1661, 10.1056/NEJM199506223322501 · DOI · Paper page
- Schulman, 1997, The duration of oral anticoagulant therapy after a second episode of venous thromboembolism, New England Journal of Medicine, 336, 393, 10.1056/NEJM199702063360601 · DOI · Paper page
- Andersson, 1984, Antithrombin III in patients with acute deep vein thrombosis during heparin treatment (subcutaneous and intravenous) and during and after treatment with oral coumarins, Thrombosis Research, 34, 333, 10.1016/0049-3848(84)90390-6 · DOI
- Fennerty, 1987, A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism, Clinical & Laboratory Haematology, 9, 17, 10.1111/j.1365-2257.1987.tb01377.x · DOI · Paper page
- Holmgren, 1985, One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis, Acta Medica Scandinavica, 218, 279, 10.1111/j.0954-6820.1985.tb06125.x · DOI
- Lagerstedt, 1985, Need for long term anticoagulant treatment in symptomatic calf vein thrombosis, Lancet, 2, 515, 10.1016/S0140-6736(85)90459-3 · DOI · Paper page
- O'Sullivan, 1972, Duration of anticoagulant therapy in venous thrombo-embolism, Medical Journal of Australia, 2, 1104, 10.5694/j.1326-5377.1972.tb103752.x · DOI
- Schulman, 1985, The duration of oral anticoagulation after deep vein thrombosis. A randomized study, Acta Medica Scandinavica, 217, 547, 10.1111/j.0954-6820.1985.tb03261.x · DOI
- Sudlow, 1992, Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism, Lancet, 340, 873, 10.1016/0140-6736(92)93285-U · DOI · Paper page
- Collins, 1987, Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews, Statistics in Medicine, 6, 245, 10.1002/sim.4780060308 · DOI · Paper page
- Hull, 1979, Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis, New England Journal of Medicine, 301, 855, 10.1056/NEJM197910183011602 · DOI · Paper page
- Koopman, 1996, The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home, New England Journal of Medicine, 334, 682, 10.1056/NEJM199603143341102 · DOI · Paper page
- Lagerstedt, 1985, Need for long term anticoagulant treatment in symptomatic calf vein thrombosis, Lancet, 2, 515, 10.1016/S0140-6736(85)90459-3 · DOI · Paper page
- Levine, 1996, A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis, New England Journal of Medicine, 334, 677, 10.1056/NEJM199603143341101 · DOI · Paper page
- Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, Journal of the National Cancer Institute, 22, 719
- Prandoni, 1996, The long-term clinical course of acute deep venous thrombosis, Annals of Internal Medicine, 125, 1, 10.7326/0003-4819-125-1-199607010-00001 · DOI · Paper page
- Prins, 1999, The optimal duration of secondary prevention with oral anticoagulants in patients with venous thromboembolism. A decision analysis, Thromb & Haemost, Suppl, 7
- Prins, 1999, Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S: a decision analysis, Thromb & Haemost, Suppl, 180
- Yusuf, 1985, Beta blockade during and after myocardial infarction: an overview of the randomized trials, Progress in Cardiovascular Diseases, 27, 335, 10.1016/S0033-0620(85)80003-7 · DOI · Paper page
Cited by
Schünemann, H. J., Jaeschke, R., Cook, D. J., Bria, W. F., El-Solh, A. A., Ernst, A., Fahy, B. F., Gould, M. K., Horan, K. L., Krishnan, J. A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-197st · Cited by 577
Boutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., Hirsh, J., & Kearon, C. (2011) · BMJ · doi:10.1136/bmj.d3036 · Cited by 371
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
Platelet-derived porous nanomotor for thrombus therapy
Wan, M., Wang, Q., Wang, R., Wu, R., Li, T., Fang, D., Huang, Y., Yu, Y., Fang, L., Wang, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz9014 · Cited by 276
Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135
Metadata
- Authors
- Hutten, B., & Prins, M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2000-04-24
- Issue
- 2
- Pages
- CD001333-CD001333
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4249177926
- Cited by
- 43
- References
- 2
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.